Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk. Here, we aime...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Korean Association for the Study of the Liver
2024-01-01
|
| Colección: | Clinical and Molecular Hepatology |
| Materias: | |
| Acceso en línea: | http://e-cmh.org/upload/pdf/cmh-2023-0328.pdf |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|